Search for Clinical Trial Results
Hematologic Neoplasms - 25 Studies Found
Status | Study |
Recruiting |
Study Name: Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors Condition: Hematologic Neoplasms Date: 2011-06-15 Interventions:
|
Not yet recruiting |
Study Name: Prophylactic Early PN in HPT/BMT Condition: Hematologic Neoplasms Date: 2017-03-08 Interventions:
|
Recruiting |
Study Name: A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Condition: Hematologic Neoplasms Date: 2016-09-06 Interventions:
|
Recruiting |
Study Name: Platelet Transfusion Requirements in Hematopoietic Transplantation Condition: Hematologic Neoplasms Date: 2016-01-06 Interventions: Drug: Tranexamic Acid |
Recruiting |
Study Name: Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients Condition: Hematologic Neoplasms Date: 2015-11-30 Interventions: Procedure: Allogeneic (Allo) hematopoietic stem cell transplantation |
Recruiting |
Study Name: Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units Condition: Hematologic Neoplasms Date: 2015-07-17 Interventions: Procedure: T-Cell replete haplo-transplant Infusion of haploidentical related donor peripheral blood ste |
Recruiting |
Study Name: Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Condition: Hematologic Neoplasms Date: 2015-05-18 Interventions:
|
Recruiting |
Study Name: Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Condition: Hematologic Neoplasms Date: 2014-02-12 Interventions:
|
Active, not recruiting |
Study Name: Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation Condition: Hematologic Neoplasms Date: 2013-07-31 Interventions: Drug: AG-221 AG-221 administered orally on every day of 28 day cycles until disease progression or unacc |
Active, not recruiting |
Study Name: Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy Condition: Hematologic Neoplasms Date: 2013-05-28 |